Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease
Laboratory studyOther animalsWith adelmidrol (a PEA analogue, tested alone)
This study tested palmitoylethanolamide together with adelmidrol (a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with dinitrobenzene sulfonic acid-induced experimental colitis
- Dose used in the study
- Adelmidrol 10 mg/kg daily, oral
- Duration
- Not stated precisely in the abstract
- What was measured
- NF-kB translocation, COX-2, ERK phosphorylation, TNF-alpha and IL-1beta, ICAM-1, P-selectin, nitrotyrosine, poly(ADP-ribose), diarrhea, body weight loss, myeloperoxidase activity and Bax/Bcl-2 expression
What the authors reported
Colitis raised NF-kB translocation, COX-2, ERK phosphorylation, cytokines and markers of oxidative/nitrosative stress. Adelmidrol reduced diarrhea, weight loss and myeloperoxidase activity, lowered NF-kB, COX-2, ERK, cytokines, nitrotyrosine and poly(ADP-ribose), reduced ICAM-1 and P-selectin, and shifted Bax/Bcl-2 balance toward less apoptosis, partly via PPAR-gamma.
Limits of this study
A mouse model of colitis; it cannot show effect in people with inflammatory bowel disease. Funding and conflicts not stated in the abstract.
Source
PubMed 27625036 · doi:10.1124/mol.116.105668
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.